Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/parexel-biopharmaceutical-r-et-d-statistical-sourcebook-2017-2018/descriptif_3672108
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3672108

Parexel Biopharmaceutical R&D Statistical Sourcebook 2017/2018

Langue : Anglais
Couverture de l’ouvrage Parexel Biopharmaceutical R&D Statistical Sourcebook 2017/2018
PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2017/2018 is the leading resource for statistics, trends, and proprietary market intelligence and analyses on the biopharmaceutical industry. Supported by thousands of graphs, illustrations, and analyses, the Sourcebook provides the latest intelligence on every aspect of biopharmaceutical development – from product discovery, to R&D performance and productivity, to time-to-market trends.

With real-world analysis and key contributions from leading consultancies and experts, the Sourcebook includes:
- New proprietary analysis on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials
- All-new analyses on who “owns” today’s R&D pipeline, R&D spending, and new drug/biologics approvals by company size and type (pharma vs. biotech)
- Emerging data on worldwide and company-specific R&D pipelines and product launch trends
New analysis on emerging trends in pharma and biotech licensing deals and other partnerships critical to industry’s R&D pipeline
- Drug approval statistics compiled from FDA, EMA, and other regulatory agencies
- New global R&D spending trends and other international R&D data from key markets
- International statistics on drug development output

And Much More:
- Spotlight analyses on emerging and re-emerging elements of industry’s R&D pipeline, including immunooncology, biosimilars, antibiotics, and gene therapy
- Assessments of several emerging industry controversies, including drug pricing, the wisdom of ultra-rapid new drug reviews, and R&D “overcrowding” in some parts of the new drug pipeline
- Analyses on the state, nature, and sustainability of industry’s pipeline of R&D projects
- Detailed profiles on the pipelines and emerging R&D models and structures used by leading pharma companies
- Analyses focused on the drug and biopharma markets and development pipelines within emerging countries, including brand new analyses on Korea and China
- Assessments of personalized medicine/companion diagnostics, biosimilars, orphan drugs, and other factors reshaping biopharma R&D today

PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2017/2018 is a must-have resource for the drug development industry. It is invaluable to executives and managers working in the pharma and biotech industries. The Sourcebook puts real-world data sets at your fingertips for presentations, reports, business development efforts, strategic meetings, and critical decision-making analyses.

Date de parution :

Disponible chez l'éditeur (délai d'approvisionnement : 20 jours).

819,92 €

Ajouter au panier

Thèmes de Parexel Biopharmaceutical R&D Statistical Sourcebook... :

En continuant à naviguer, vous autorisez Lavoisier à déposer des cookies à des fins de mesure d'audience. Pour en savoir plus et paramétrer les cookies, rendez-vous sur la page Confidentialité & Sécurité.
FERMER